Inventor
BURNS AARON CRAIG
US16 patents
⚠️ This page may combine multiple inventors who share the name “BURNS AARON CRAIG”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
MIRATI THERAPEUTICS INC
14 patentsUS11453683B1Sep 27, 2022
KRas G12D inhibitors
MIRATI THERAPEUTICS INC13 citations83
US11091495B2Aug 17, 2021
Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
MIRATI THERAPEUTICS INC4 citations82
US10647715B2May 12, 2020
KRas G12C inhibitors
MIRATI THERAPEUTICS INC10 citations82
US11964989B2Apr 23, 2024
KRas G12D inhibitors
MIRATI THERAPEUTICS INC2 citations71
US11220509B2Jan 11, 2022
Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
MIRATI THERAPEUTICS INC2 citations71
US11548888B2Jan 10, 2023
KRas G12C inhibitors
MIRATI THERAPEUTICS INC1 citations62
US12371435B2Jul 29, 2025
Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
MIRATI THERAPEUTICS INC0 citations61
US12304915B2May 20, 2025
SOS1 inhibitors
MIRATI THERAPEUTICS INC0 citations61
US11702418B2Jul 18, 2023
SOS1 inhibitors
MIRATI THERAPEUTICS INC0 citations61
US11492351B2Nov 8, 2022
MTA-cooperative PRMT5 inhibitors
MIRATI THERAPEUTICS INC0 citations61
US11485738B2Nov 1, 2022
Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
MIRATI THERAPEUTICS INC0 citations61
US11479551B2Oct 25, 2022
MTA-cooperative PRMT5 inhibitors
MIRATI THERAPEUTICS INC1 citations61
US12421228B2Sep 23, 2025
Naphthyridine derivatives as PRC2 inhibitors
MIRATI THERAPEUTICS INC0 citations51
US12252493B2Mar 18, 2025
Imidazo[1,2-c]pyrimidine derivatives as PRC2 inhibitors for treating cancer
MIRATI THERAPEUTICS INC0 citations51